FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

펩타이드 라이브러리

Thymalin

Thymaline / Thymic Peptide Extract

Immune & Thymic

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

작용 메커니즘

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

연구 프로토콜

연구 용도만 사용 가능. 의학적 조언은 아닙니다.

Khavinson protocols use 5-10mg intramuscularly daily for 5-10 day cycles, repeated every 6-12 months. Some protocols use sublingual or oral administration at 10-20mg daily.

연구 노트

Clinical Research Status

Thymalin has been studied in longitudinal clinical trials spanning over 15 years in elderly populations, with Khavinson's landmark study demonstrating a 46% reduction in mortality over a 12-year follow-up period in treated versus control groups. It is registered as a pharmaceutical preparation in Russia for immunodeficiency states and as an adjuvant in cancer treatment. While these results are remarkable, they have not been independently replicated in Western research settings or subjected to rigorous international peer review standards.

Key Published Findings

The most cited study showed that combined Thymalin and Epithalon treatment in elderly patients (60-80 years) reduced mortality, improved immune function, and normalized neuroendocrine regulation over 6-12 years of observation. Immunological research demonstrates restoration of T-cell subpopulation ratios, increased natural killer cell activity, and normalization of cytokine profiles in immunocompromised elderly patients. Animal studies in various species show increased lifespan, improved tumor resistance, and restoration of thymic architecture following Thymalin administration.

Safety Profile

Thymalin has been used clinically in Russia for decades with a well-established safety profile showing minimal adverse effects at standard therapeutic doses. The most commonly reported side effects are mild injection site reactions and occasional allergic responses in individuals sensitive to bovine-derived products. As an animal-derived extract, theoretical concerns about prion contamination exist, though no cases have been reported in the published literature.

Comparison to Related Compounds

Thymalin differs from synthetic thymic peptides like Thymosin Alpha-1 (Zadaxin) in that it is a complex mixture of multiple thymic peptides rather than a single defined molecule. Compared to the synthetic thymic dipeptide Thymogen (Glu-Trp), Thymalin contains a broader range of immunoactive components but has less molecular specificity. Thymalin's multi-component nature is considered both an advantage (multiple synergistic mechanisms) and a limitation (difficult to standardize and characterize) compared to single-peptide approaches.

Community Observations

Users in the longevity community often use Thymalin as part of seasonal immune optimization protocols, particularly during winter months or periods of high infection risk. Many combine it with Epithalon in what is sometimes called the "Khavinson protocol" for comprehensive anti-aging effects targeting both immune function and cellular longevity. The requirement for intramuscular injection and limited sourcing options outside Russia present practical barriers for many interested users.

반감기

~Variable (mixture)

재조성

Sterile saline or bacteriostatic water for injection

보관

건조한 상태

Refrigerate 2-8C.

재조성된 상태

Use within 24 hours of reconstitution.

미국 법적 상태

Research chemical (approved in Russia)

또는 알려진 이름으로

ThymalineThymic Peptide Extract

자주 묻는 질문

Thymalin란 무엇인가요?

Thymalin (also known as Thymic Peptide Extract or Thymalin) is a polypeptide complex extracted from calf thymus glands, developed by Professors Vladimir Khavinson and Vyacheslav Morozov at the St. Petersburg Institute of Bioregulation and Gerontology as an immunomodulatory bioregulator. It was one of the earliest bioregulator peptides investigated for anti-aging applications, with research spanning over 40 years in Russian gerontological medicine. Thymalin is administered via intramuscular injection and targets restoration of thymic function and T-cell immunity that declines with age.

Thymalin는 어떻게 작용하나요?

Bovine thymus extract containing a mixture of thymic peptide factors. Restores T-cell immunity, promotes thymic regeneration, and modulates immune system homeostasis. Part of the Khavinson bioregulator family targeting the thymus and immune system.

Thymalin의 미국 규제 현황은 어떤가요?

Research chemical (approved in Russia)

Thymalin의 반감기는 얼마인가요?

~Variable (mixture)

Thymalin의 다른 이름은 무엇인가요?

Thymaline, Thymic Peptide Extract

Peptide Contacts는 정보 제공을 위해 연구 기반 요약을 제공합니다. 우리는 공급업체 문서를 호스팅, 배포하거나 지지하지 않습니다. 모든 테스트 보고서, GMP 인증서 및 공급업체 통신은 구매자는 직접 요청하고 확인해야 합니다. 이 플랫폼에서 제공되는 어떠한 정보도 법적, 의학적 또는 전문적인 조언을 대체하지 않습니다. 사용자는 모든 관련 지역법, 주법 및 연방법에 부합하기 위해 공급업체 자격 증명을 검증하고 구매하기 전에 준수해야 합니다. 이 플랫폼의 사용은 이러한 책임을 완전히 지닌 것으로 간주됩니다.

전체 공지사항 읽기